Immunopathogenesis of Keratoconjunctivitis Sicca in the Dog

Veterinary Clinics of North America - Small Animal Practice

Volumn 38, Issue 2, 2008, Pages 251-268

  Williams, David L ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST JOHN S COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOSPORIN; IMMUNOGLOBULIN A; INTERLEUKIN 4; INTERLEUKIN 5; LA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; OPTIMMUNE; PILOCARPINE; PIMECROLIMUS; RITUXIMAB; RO ANTIBODY; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ANDROGEN DEFICIENCY; CD4+ T LYMPHOCYTE; DISEASE MODEL; DOG DISEASE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; KERATOCONJUNCTIVITIS SICCA; LACRIMATION; LEISHMANIASIS; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOUSE STRAIN; NONHUMAN; OPHTHALMOSCOPY; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SJOEGREN SYNDROME; TEAR FILM; TEAR FLOW; ANIMAL; ANIMAL DISEASE; AUTOIMMUNE DISEASE; DIFFERENTIAL DIAGNOSIS; DOG; IMMUNOLOGY; LACRIMAL FLUID; PATHOLOGY; SECRETION;

CANIS FAMILIARIS; RODENTIA;

ANIMALS; AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; KERATOCONJUNCTIVITIS SICCA; TEARS;

EID: 43149122251     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.12.002     Document Type: Review

References (92)

1. Gelatt K.N., Peiffer Jr. R.L., Erickson J.L., et al. Evaluation of tear formation in the dog, using a modification of the Schirmer tear test. J Am Vet Med Assoc 166 (1975) 368-370
2. Helper L.C. Keratoconjunctivitis sicca in dogs. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 81 (1976) 624-628
3. Kaswan R., Pappas Jr. C., Wall K., et al. Survey of canine tear deficiency in veterinary practice. Adv Exp Med Biol 438 (1998) 931-939
4. Peirce V, Harmer E, Williams DL. Prevalence of keratoconjunctivitis in the canine population: Shirmer tear tests in one thousand normal dogs. Veterinary Journal submitted.
5. Kaswan R.L., and Salisbury M.A. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthal 107 (1989) 1210-1216
6. Lambert D.W. Physiology of the tear film. In: Smolin G., and Thoft R.A. (Eds). The cornea (1994), Little Brown & Co, New York 439-455
7. Gipson I.K., Yankauckas M., Spurr-Michaud S.J., et al. Characteristics of a glycoprotein in the ocular surface glycocalyx. Invest Ophthalmol Vis Sci 33 (1992) 218-227
8. Gipson I.K., Hori Y., and Argueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2 (2004) 131-148
9. Stern M.E., Gao J., Siemasko K.F., et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 78 (2004) 409-416
10. van der Woerdt A., and Adamcak A. Comparison of absorptive capacities of original and modified Schirmer tear test strips in dogs. J Am Vet Med Assoc 216 (2000) 1576-1577
11. Afonso A.A., Monroy D., Stern M.E., et al. Evaluation of results for Schirmer tear tests conducted with and without application of a topical anesthetic in clinically normal dogs of 5 breeds. Am J Vet Res 61 (2000) 1422-1425
12. Williams D.L. Analysis of tear uptake by the Schirmer tear test strip in the canine eye. Vet Ophthalmol 8 (2005) 325-330
13. Brown M.H., Galland J.C., Davidson H.J., et al. The phenol red thread test in dogs. Progress in Veterinary and Comparative Ophthalmology 6 (1996) 274-277
14. Saito A., and Kotani T. Estimation of lacrimal level and testing methods on normal beagles. Vet Ophthalmol 4 (2001) 7-11
15. Yokoi N., Bron A., Tiffany J., et al. Reflective meniscometry: a non-invasive method to measure tear meniscus curvature. Br J Ophthalmol 83 (1999) 92-97
16. Saito A., and Kotani T. Tear production in dogs with epiphora and corneal epitheliopathy. Vet Ophthalmol 2 (1999) 173-178
17. Ofri R., Orgad K., Kass P.H., et al. Canine meibometry: establishing baseline values for meibomian gland secretions in dogs. Vet J 174 (2007) 536-540
18. Hartley C., Williams D.L., and Adams V.J. Effect of age, gender, weight, and time of day on tear production in normal dogs. Vet Ophthalmol 9 (2006) 53-57
19. Williams D.L., Pierce V., Mellor P., et al. Reduced tear production in three canine endocrinopathies. J Small Anim Pract 48 (2007) 252-256
20. Kaswan R.L., Martin C.L., and Chapman Jr. W.L. Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. Am J Vet Res 45 (1984) 112-118
21. Izci C., Celik I., Alkan F., et al. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. Am J Vet Res 63 (2002) 688-694
22. Tighe A, Williams DL. Analysis of lymphocyte populations in nictitans glands of dogs with keratoconjunctivitis sicca. Veterinary Journal submitted.
23. Naranjo C., Fondevila D., Leiva M., et al. Characterization of lacrimal gland lesions and possible pathogenic mechanisms of keratoconjunctivitis sicca in dogs with leishmaniosis. Vet Parasitol 133 (2005) 37-47
24. Kaswan R.L., Martin C.L., and Dawe D.L. Keratoconjunctivitis sicca: immunological evaluation of 62 canine cases. Am J Vet Res 46 (1985) 376-383
25. Kaswan R.L., Martin C.L., and Dawe D.L. Rheumatoid factor determination in 50 dogs with keratoconjunctivitis sicca. J Am Vet Med Assoc 183 (1983) 1073-1075
26. Kahan B.D., van Buren C.T., Flechner S.M., et al. Clinical and experimental studies with cyclosporine in renal transplantation. Surgery 97 (1985) 125-140
27. Olivry T., Rivierre C., Jackson H.A., et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 13 (2002) 77-87
28. Hardie R.J., Gregory S.P., Tomlin J., et al. Cyclosporine treatment of anal furunculosis in 26 dogs. J Small Anim Pract 46 (2005) 3-9
29. Bexfield N., Watson P.J., and Herrtage M. Management of myasthenia gravis using cyclosporine in 2 dogs. J Vet Intern Med 20 (2006) 1487-1490
30. Morgan R.V., and Abrahams K.L. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc 99 (1991) 1043-1046
31. Olivero D.K., Davidson M.G., English R.V., et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc 199 (1991) 1039-1042
32. Sansom J., Barnett K.C., Neumann W., et al. Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Vet Rec 137 (1995) 504-507
33. Williams D.L. A comparative approach to topical cyclosporine therapy. Eye 11 (1997) 453-464
34. Berdoulay A., English R.V., and Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 8 (2005) 225-232
35. Nell B., Walde I., Billich A., et al. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 8 (2005) 39-46
36. Williams D.L. Efficacy of topical tacrolimus in dogs with cyclosporine-non-responsive keratoconjunctivitis sicca (2006), British Small Animal Veterinary Association, Birmingham, UK
37. Glenn J.B., and Lawson D.D. A modified technique of parotid duct transposition for the treatment of keratoconjunctivitis sicca in the dog. Vet Rec 88 (1971) 210-213
38. Yoshida A., Fujihara T., and Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res 68 (1999) 541-546
39. Moore C.P., McHugh J.B., Thorne J.G., et al. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci 42 (2001) 653-659
40. Gilger B.C., Rose P.D., Davidson M.G., et al. Low-dose oral administration of interferon-alpha for the treatment of immune-mediated keratoconjunctivitis sicca in dogs. J Interferon Cytokine Res 19 (1999) 901-905
41. Ferraccioli G.F., Salaffi F., De Vita S., et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 14 (1996) 367-371
42. Amadori M. The role of IFN-alpha as homeostatic agent in the inflammatory response: a balance between danger and response?. J Interferon Cytokine Res 27 (2007) 181-189
43. Smith E.M., Buyukmihci N.C., and Farver T.B. Effect of topical pilocarpine treatment on tear production in dogs. J Am Vet Med Assoc 205 (1994) 1286-1289
44. Rubin L.F., and Aguirre G. Clinical use of pilocarpine for keratoconjuctivitis in dogs and cats. J Am Vet Med Assoc 151 (1967) 313-320
45. Adamson T.C., Fox R.I., Frisman D.M., et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol 130 (1983) 203-208
46. Lindahl G., Hedfors E., Klareskog L., et al. Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjogren's syndrome. Clin Exp Immunol 61 (1985) 475-482
47. Matsumoto I., Tsubota K., Satake Y., et al. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjogren's syndrome. J Clin Invest 97 (1996) 1969-1977
48. Namekawa T., Kuroda K., Kato T., et al. Identification of Ro(SSA) 52 kDa reactive T cells in labial salivary glands from patients with Sjogren's syndrome. J Rheumatol 22 (1995) 2092-2099
49. Eggleton P. Stress protein-polypeptide complexes acting as autoimmune triggers. Clin Exp Immunol 134 (2003) 6-8
50. Daridon C., Guerrier T., Devauchelle V., et al. Polarization of B effector cells in Sjogren's syndrome. Autoimmun Rev 6 (2007) 427-431
51. Carbone A., Gloghini A., and Ferlito A. Pathological features of lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis versus low-grade B-cell lymphoma of the malt type. Ann Otol Rhinol Laryngol 109 (2000) 1170-1175
52. Konttinen Y.T., Kemppinen P., Koski H., et al. Th1 cytokines are produced in labial salivary glands in Sjogren's syndrome, but also in healthy individuals. Scand J Rheumatol 28 (1999) 106-112
53. Pertovaara M., Antonen J., and Hurme M. Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Ann Rheum Dis 65 (2006) 666-670
54. Mitsias D.I., Tzioufas A.G., Veiopoulou C., et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 128 (2002) 562-568
55. Barabino S., and Dana M.R. Animal models of dry eye: a critical assessment of opportunities and limitations. Invest Ophthalmol Vis Sci 45 (2004) 1641-1646
56. Jabs D.A., Enger C., and Predergast R.A. Murine models of Sjogren's syndrome. Evolution of the lacrimal gland inflammatory lesions. Invest Ophthalmol Vis Sci 32 (1991) 371-380
57. Jabs D.A., Lee B., Whittum-Hudson J., et al. The role of Fas-Fas ligand-mediated apoptosis in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 42 (2001) 399-401
58. Jabs D.A., Lee B., and Prendergast R.A. Role of T cells in the pathogenesis of autoimmune lacrimal gland disease in MRL/Mp-lpr/lpr mice. Curr Eye Res 16 (1997) 909-916
59. Jabs D.A., Burek C.L., Hu Q., et al. Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice. Cell Immunol 141 (1992) 496-507
60. Jabs D.A., Prendergast R.A., Rorer E.M., et al. Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 42 (2001) 2567-2571
61. Jabs D.A., Lee B., Whittum-Hudson J.A., et al. Th1 versus Th2 immune responses in autoimmune lacrimal gland disease in MRL/Mp mice. Invest Ophthalmol Vis Sci 41 (2000) 826-831
62. Akpek E.K., Jabs D.A., Gerrard H.C., et al. Chemokines in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 45 (2004) 185-190
63. Jabs D.A., Gerard H.C., Wei Y., et al. Inflammatory mediators in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 45 (2004) 2293-2298
64. Robinson C.P., Yamachika S., Bounous D.I., et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 41 (1998) 150-156
65. Robinson C.P., Cornelius J., Bounous D.E., et al. Characterization of the changing lymphocyte populations and cytokine expression in the exocrine tissues of autoimmune NOD mice. Autoimmunity 27 (1998) 29-44
66. Gao J., Killedar S., Cornelius J.G., et al. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 26 (2006) 90-103
67. Rosignoli F., Roca V., Meiss R., et al. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol 142 (2005) 411-418
68. Humphreys-Beher M.G., Yamachika S., Yamamoto H., et al. Salivary gland changes in the NOD mouse model for Sjogren's syndrome: is there a non-immune genetic trigger?. Eur J Morphol 36 (1998) 247-251
69. Humphreys-Beher M.G., and Peck A.B. New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Arch Oral Biol 44 (1999) S21-S25
70. Robinson C.P., Brayer J., Yamachika S., et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 95 (1998) 7538-7543
71. Nguyen K.H., Brayer J., Cha S., et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 43 (2000) 2297-2306
72. Nguyen C., Cornelius J., Singson E., et al. Role of complement and B lymphocytes in Sjogren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 43 (2006) 1332-1339
73. Zouhkri D. Effect of inflammation on lacrimal gland function. Exp Eye Res 82 (2006) 885-898
74. Gao J., Schwalb T.A., Addeo J.V., et al. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea 17 (1998) 654-663
75. Zoukhri D., and Kublin D.L. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2 (2001) 925-932
76. Papas A.S., Fernandez M.M., Castano R.A., et al. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogren's syndrome. Adv Exp Med Biol 438 (1998) 973-978
77. Yamachika S., Nanni J.M., Nguyen K.H., et al. Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjogren's syndrome. J Rheumatol 25 (1998) 2371-2380
78. Fye K.H., Terasaki P.I., Michalski J.P., et al. Relationship of HLA-Dw3 and HLA-B8 to Sjogren's syndrome. Arthritis Rheum 21 (1978) 337-342
79. Toda I., Sullivan B.D., Rocha E.M., et al. Impact of gender on exocrine gland inflammation in mouse models of Sjogren's syndrome. Exp Eye Res 69 (1999) 355-366
80. Porola P., Laine M., Virkki L., et al. The influence of sex steroids on Sjogren's syndrome. Ann N Y Acad Sci 1108 (2007) 426-432
81. Sullivan D.A., and Edwards J.A. Androgen stimulation of lacrimal gland function in mouse models of Sjogren's syndrome. J Steroid Biochem Mol Biol 60 (1997) 237-245
82. Ono M., Rocha F.J., and Sullivan D.A. Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-lpr/lpr mouse model of Sjogren's syndrome. Exp Eye Res 61 (1995) 659-666
83. Sato H., Ariga E.H., and Sullivan D.A. Impact of androgen therapy in Sjogren's syndrome: hormonal influence on lymphocyte populations and Ia expression in lacrimal glands of MRL/Mp-lpr/lpr mice. Invest Ophthalmol Vis Sci 33 (1992) 2537-2545
84. Toda I., Wickham L.A., and Sullivan D.A. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol 86 (1998) 59-71
85. Cha S., van Blockland S.C., Versnel M.A., et al. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet 18 (2001) 143-160
86. Wang Y., Virji A.S., Howard P., et al. Detection of cleaved alpha-fodrin autoantigen in Sjogren's syndrome: apoptosis and co-localisation of cleaved alpha-fodrin with activated caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) in labial salivary glands. Arch Oral Biol 51 (2006) 558-566
87. Fujihara T., Fujita H., Tsubota K., et al. Preferential localization of CD8+ alpha E beta 7+ T cells around acinar epithelial cells with apoptosis in patients with Sjogren's syndrome. J Immunol 163 (1999) 2226-2235
88. Nagaraju K., Cox A., Casciola-Rosen L., et al. Novel fragments of the Sjogren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 44 (2001) 2376-2386
89. Saegusa K., Ishimaru N., Yanagi K., et al. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren's syndrome. J Immunol 169 (2002) 1050-1057
90. Dawson L.J., Fox P.C., and Smith P.M. Sjogren's syndrome-the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 45 (2006) 792-798
91. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 12 (1994) 991-1045
92. Bredberg A., Henriksson G., Larsson A., et al. Sjogren's syndrome and the danger model. Rheumatology (Oxford) 44 (2005) 965-970